Free Trial

CVS Health (CVS) Stock Forecast & Price Target

CVS Health logo
$77.03 +0.10 (+0.13%)
As of 11:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CVS Health - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
21

Based on 25 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 4 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for CVS.

Consensus Price Target

$79.80
3.60% Upside
According to the 25 analysts' twelve-month price targets for CVS Health, the average price target is $79.80. The highest price target for CVS is $103.00, while the lowest price target for CVS is $65.00. The average price target represents a forecasted upside of 3.60% from the current price of $77.03.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

TypeCurrent Forecast
10/9/24 to 10/9/25
1 Month Ago
9/9/24 to 9/9/25
3 Months Ago
7/11/24 to 7/11/25
1 Year Ago
10/10/23 to 10/9/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
19 Buy rating(s)
19 Buy rating(s)
17 Buy rating(s)
12 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$79.80$77.89$75.38$74.05
Forecasted Upside3.60% Upside8.62% Upside16.45% Upside12.27% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.34
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside3.72% Upside1,099.09% Upside170.78% Upside
News Sentiment Rating
Positive News

See Recent CVS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/9/2025Mizuho
3 of 5 stars
Ann Hynes
Ann Hynes
3 of 5 stars
Boost TargetOutperform$76.00 ➝ $88.00+14.37%
10/7/2025Wells Fargo & Company
3 of 5 stars
Stephen Baxter
Stephen Baxter
4 of 5 stars
Boost TargetOverweight$84.00 ➝ $103.00+34.01%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
9/22/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$80.00 ➝ $85.00+14.17%
9/8/2025Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
9/5/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$72.00 ➝ $77.00+4.30%
9/4/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $87.00+18.63%
8/26/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$78.00+9.52%
8/18/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$67.00 ➝ $79.00+15.23%
8/14/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
8/14/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$71.00 ➝ $82.00+24.41%
8/4/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $82.00+31.12%
7/16/2025Bernstein Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetMarket Perform$78.00 ➝ $72.00+12.86%
6/30/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$74.00 ➝ $80.00+16.43%
5/12/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$82.00 ➝ $84.00+32.07%
5/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$74.00 ➝ $81.00+19.23%
3/21/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$72.00 ➝ $74.00+7.70%
2/18/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$77.00+16.93%
2/18/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $81.00+23.71%
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$55.00 ➝ $75.00+18.61%
2/12/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
1/30/2025Edward Jones
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
1/27/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$60.00 ➝ $65.00+15.59%
12/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$66.00 ➝ $66.00+11.73%
11/25/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$73.00 ➝ $80.00+33.11%
5/2/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$95.00 ➝ $77.00+41.73%
5/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$85.00 ➝ $74.00+36.08%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$94.00+19.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:04 AM ET.


Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 7, 2025. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CVS Health Co.:

  • The current stock price is around $78, which reflects a positive outlook from several analysts who have rated the stock as a "buy" or "outperform."
  • CVS Health Co. has a strong dividend yield of approximately 3.4%, providing investors with a steady income stream through its quarterly dividends.
  • Analysts have set a consensus target price of about $78.25, indicating potential for price appreciation based on current market conditions.
  • The company has shown resilience with earnings per share (EPS) guidance for FY 2025 set between 6.300 and 6.400, suggesting stable financial performance ahead.
  • Recent upgrades from multiple research firms, including a notable increase in price targets, highlight growing confidence in CVS Health Co.'s future prospects.

CVS Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CVS Health Co. for these reasons:

  • Despite positive ratings, Zacks Research recently downgraded CVS Health Co. from a "strong-buy" to a "hold," indicating some analysts may have concerns about its growth potential.
  • The company's dividend payout ratio is currently at 74.30%, which may raise concerns about sustainability, especially if earnings do not meet expectations.
  • Insider selling activity, such as the recent sale of shares by a director, could signal a lack of confidence in the stock's short-term performance.
  • With a significant number of analysts issuing "buy" ratings, there may be heightened expectations that could lead to volatility if the company fails to meet these projections.
  • Market conditions and competition in the healthcare sector could pose risks to CVS Health Co.'s growth and profitability, making it a more cautious investment choice.

CVS Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $79.80, with a high forecast of $103.00 and a low forecast of $65.00.

25 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last twelve months. There are currently 4 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 3.60% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 3 upgrades and 1 downgrade by analysts.

Analysts like CVS Health more than other "medical" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CVS compares to other companies.


This page (NYSE:CVS) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners